An FDA advisory committee delivered unanimous support for Moderna’s mRNA-1010 influenza vaccine, advancing the product toward potential approval despite an earlier FDA review dispute. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that benefits outweigh risks for adults ages 50 to 64, and again 9-0 for those 65 and older. Moderna is pursuing standard approval for the 50-to-64 cohort and an accelerated pathway for the 65-and-older group, with a decision expected by Aug. 5. Panel discussion materials suggested the data cleared sufficient hurdles for traditional approval in the younger group and supported expedited consideration in the older cohort. The vote came after the vaccine became controversial earlier in the year, when an FDA official briefly refused to accept it for review. Moderna’s mRNA manufacturing and platform are central to its strategy for rapid strain updates and scale. If the FDA follows the panel, mRNA-1010 could join an mRNA influenza toolkit increasingly positioned for faster response to emerging or pandemic strains.